NCT00716742

Safety and Efficacy Study of Bimatoprost, Latanoprost, and Travoprost in Patients With Elevated Intraocular Pressure (IOP) and Open-angle Glaucoma (OAG)

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 1,099 (actual)
• Sponsor: Allergan · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To investigate the effectiveness of the newer IOP-lowering therapies, as prescribed in normal clinical practice, in larger patient numbers. Patients will be assessed at baseline, at each follow-up visit (follow-up visits are variable as per physician discretion) and at final follow-up visit.

Conditions

• Open-Angle Glaucoma
• Ocular Hypertension

Interventions

Type	Name	Description
DRUG	bimatoprost 0.03%, latanoprost 0.005%, and travoprost 0.004%	1 drop in eye(s) every evening

Timeline

• Start date: 2004-09-01
• Primary completion: 2007-09-01
• Completion: 2009-09-01
• First posted: 2008-07-16
• Last updated: 2012-01-06
• Results posted: 2012-01-06

Locations

1 site across 1 country: United States